Canada Pension Plan Investment Board’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-18,300
Closed -$254K – 1696
2026
Q1
$254K Sell
18,300
-7,800
-30% -$124K ﹤0.01% 1487
2025
Q4
$424K Buy
26,100
+9,100
+54% +$149K ﹤0.01% 1364
2025
Q3
$254K Sell
17,000
-2,900
-15% -$35.3K ﹤0.01% 1097
2025
Q2
$232K Buy
19,900
+6,700
+51% +$60.9K ﹤0.01% 1089
2025
Q1
$98.1K Sell
13,200
-16,400
-55% -$126K ﹤0.01% 1138
2024
Q4
$177K Buy
29,600
+7,500
+34% +$41.4K ﹤0.01% 1198
2024
Q3
$113K Sell
22,100
-5,100
-19% -$22.2K ﹤0.01% 1155
2024
Q2
$98.5K Buy
+27,200
New +$86.3K ﹤0.01% 1183
2022
Q1
– Sell
-290
Closed -$8K – 1307
2021
Q4
$8K Sell
290
-597
-67% -$18.3K ﹤0.01% 1406
2021
Q3
$30K Buy
+887
New +$32.1K ﹤0.01% 1311
2021
Q1
– Sell
-138,458
Closed -$8.19M – 1269
2020
Q4
$8.19M Buy
+138,458
New +$7.14M 0.01% 516

Other funds holding ADPT

Canada Pension Plan Investment Board's ADPT Position: Q2 2026 in Review

Canada Pension Plan Investment Board sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 18,300 shares — an estimated $254K sold.

Canada Pension Plan Investment Board first reported a position in ADPT in Q4 2020 and held it in 11 quarters. The position peaked at $8.19M in Q4 2020. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Canada Pension Plan Investment Board reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Canada Pension Plan Investment Board sold 18,300 Adaptive Biotechnologies shares in Q2 2026, an estimated $254K.
  • Canada Pension Plan Investment Board first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 11 quarters.
  • Canada Pension Plan Investment Board's Adaptive Biotechnologies position peaked at $8.19M in Q4 2020.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Canada Pension Plan Investment Board's 13F filing for Q2 2026, filed 14 Aug 2026.